{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:49:20Z","timestamp":1789148960018,"version":"build-2803163510"},"reference-count":172,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Oral Janus kinase (JAK) inhibitors have become an important therapeutic class in dermatology, with approved indications including atopic dermatitis and alopecia areata. Owing to their broad immunomodulatory effects and rapid onset of action, these agents are increasingly used off label for a variety of inflammatory skin disorders that are often refractory to standard therapies. The objective of this review was to provide a comprehensive overview of the published literature on the off-label dermatologic use of oral JAK inhibitors, summarizing clinical outcomes, safety profiles and treatment durations reported in real-world settings. Materials and Methods: A literature search was conducted in PubMed to identify case reports and case series describing off-label dermatologic use of baricitinib, abrocitinib, upadacitinib, and ritlecitinib. Extracted data included authorship and year, article type, treatment regimen, treatment duration and follow-up, prior systemic therapies, clinical outcomes, and reported adverse events. Results: A total of 136 articles were included, comprising 45 articles on abrocitinib (63 patients), 55 on upadacitinib (94 patients), 35 on baricitinib (45 patients), and 2 on ritlecitinib (2 patients). Across a wide spectrum of dermatological conditions, oral JAK inhibitors showed consistent clinical efficacy. Responses were frequently rapid and disease control was often maintained over several months of treatment. In many cases, dose reduction or treatment discontinuation did not lead to immediate relapse. Overall tolerability was favorable, with adverse events reported in a minority of patients and predominantly described as mild and transient. Conclusions: Although our data is limited to case-based literature, this review highlights the broad off-label therapeutic potential of oral JAK inhibitors in dermatology. Their rapid onset of action, sustained clinical responses, frequent maintenance of remission after dose tapering or discontinuation and generally acceptable safety profile support their consideration as treatment options in selected patients.<\/jats:p>","DOI":"10.3390\/medicina62010190","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T14:46:33Z","timestamp":1768574793000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"first","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3446-6648","authenticated-orcid":false,"given":"Francesco","family":"D\u2019Oria","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two Phase 3 Trials of Baricitinib for Alopecia Areata","volume":"386","author":"King","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the Treatment of Alopecia Areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.21630","article-title":"Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis with Inadequate Response, Intolerance or Contraindication to Ciclosporin: Results from a Randomized, Placebo-Controlled, Phase III Clinical Trial (BREEZE-AD4)","volume":"187","author":"Bieber","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: A Review in Moderate to Severe Atopic Dermatitis","volume":"23","author":"Hoy","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/10600280221096713","article-title":"Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis","volume":"57","author":"Perche","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: First Approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2147\/TCRM.S338661","article-title":"Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives","volume":"18","author":"Niculet","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jcph.2347","article-title":"Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study","volume":"64","author":"Martin","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic Dermatitis","volume":"405","author":"Brunner","year":"2025","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of Care for the Management of Atopic Dermatitis in Adults with Phototherapy and Systemic Therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Kubo, S., Nakayamada, S., Sakata, K., Kitanaga, Y., Ma, X., Lee, S., Ishii, A., Yamagata, K., Nakano, K., and Tanaka, Y. (2018). Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01510"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and Safety of Abrocitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis (JADE MONO-1): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jcph.1513","article-title":"Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib","volume":"60","author":"Mohamed","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00403-025-03890-z","article-title":"Off-Label Use of JAK1 Inhibitor Upadacitinib in Dermatology","volume":"317","author":"Zhang","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/1440-1681.13704","article-title":"Efficacy and Safety of Baricitinib for the Treatment of Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"49","author":"Wang","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.36849\/jdd.7360","article-title":"Off-Label Use of Baricitinib in Dermatology","volume":"22","author":"Shah","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful Treatment of Recalcitrant Mucous Membrane Pemphigoid with Multisystem Involvement with Baricitinib and Methotrexate","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e38854","DOI":"10.1097\/MD.0000000000038854","article-title":"Epidermolysis Bullosa Pruriginosa Treated with Baricitinib: A Case Report","volume":"103","author":"He","year":"2024","journal-title":"Medicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jdcr.2024.12.017","article-title":"Bullous Pemphigoid Treated with Baricitinib as Steroid-Sparing Therapy for a Patient with Uncontrolled Diabetes","volume":"57","author":"Heo","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1111\/ced.15344","article-title":"Effective Treatment of Refractory Lichen Planus Pemphigoides with a Janus Kinase-1\/2 Inhibitor","volume":"47","author":"Moussa","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent Bullous Pemphigoid and Plaque Psoriasis Successfully Treated with Janus Kinase Inhibitor Baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2169\/internalmedicine.4646-20","article-title":"Drug-Induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-\u03b1 and IL-6 Therapy in a Patient with Rheumatoid Arthritis","volume":"59","author":"Yoshikawa","year":"2020","journal-title":"Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/ajd.14345","article-title":"Successful Treatment of Infantile Refractory Bullous Pemphigoid with Baricitinib","volume":"65","author":"Zhou","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/ced.15044","article-title":"Baricitinib for Recalcitrant Subacute Cutaneous Lupus Erythematosus with Concomitant Frontal Fibrosing Alopecia","volume":"47","author":"Kreuter","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rossano, M., Conti, E.A., Bocca, P., Volpi, S., Mastrangelo, A., Cavalli, R., Gattorno, M., Minoia, F., and Filocamo, G. (2023). Novel Heterozygous TREX1 Mutation in a Juvenile Systemic Lupus Erythematosus Patient with Severe Cutaneous Involvement Treated Successfully with Jak-Inhibitors: A Case Report. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1288675"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1111\/1346-8138.16741","article-title":"Blaschko Linear Lupus Erythematosus Treated with Baricitinib: A Case Report","volume":"50","author":"Zhan","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2417965","DOI":"10.1080\/09546634.2024.2417965","article-title":"Successful Treatment of Cutaneous Polyarteritis Nodosa with Baricitinib","volume":"35","author":"Zhou","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1346-8138.16980","article-title":"Successful Treatment with Baricitinib of Linear Morphea Following the Lines of Blaschko Mimicking Lichen Striatus","volume":"51","author":"Zou","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jdcr.2023.07.037","article-title":"Janus Kinase Inhibition for the Treatment of Refractory Frontal Fibrosing Alopecia: A Case Series and Review of the Literature","volume":"40","author":"Dunn","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2274816","DOI":"10.1080\/09546634.2023.2274816","article-title":"Alleviation of Isolated Nail Lichen Planus by the JAK1\/2 Inhibitor Baricitinib: A Case Report","volume":"34","author":"He","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e15712","DOI":"10.1111\/dth.15712","article-title":"Successfully Treated Extragenital Lichen Sclerosus in a 2-year-old Boy by Baricitinib Assessed by Dermoscopy: A Case Report","volume":"35","author":"Su","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/ajd.14172","article-title":"Baricitinib Treatment of Extragenital Lichen Sclerosus Caused by COVID-19 Vaccine","volume":"64","author":"Wang","year":"2023","journal-title":"Australas. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2050313X241235444","DOI":"10.1177\/2050313X241235444","article-title":"Use of Baricitinib in a Patient with Treatment-Resistant Pyoderma Gangrenosum","volume":"12","author":"Bechard","year":"2024","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Burleigh, A., Moraitis, E., Al Masroori, E., Al-Abadi, E., Hong, Y., Omoyinmi, E., Titheradge, H., Stals, K., Jones, W.D., and Gait, A. (2023). Case Report: ISG15 Deficiency Caused by Novel Variants in Two Families and Effective Treatment with Janus Kinase Inhibition. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1287258"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/pde.15667","article-title":"A Case of Mother and Child with CANDLE Syndrome: Diagnosis and Subsequent Treatment with Baricitinib","volume":"41","author":"Guo","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/ced.14712","article-title":"Successful Use of Baricitinib in the Treatment of Refractory Rheumatoid Arthritis-associated Sweet Syndrome","volume":"46","author":"Nousari","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2147\/CCID.S446468","article-title":"Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor","volume":"17","author":"Yang","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CCID.S412520","article-title":"A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis","volume":"16","author":"Zhou","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_41","first-page":"1006","article-title":"Baricitinib in the Treatment of Eosinophilic Pustular Folliculitis Resistant to Indomethacin","volume":"23","author":"Liu","year":"2025","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Yu, Y., Ding, X., Guo, F., Ze, K., Sun, X., and Li, X. (2023). Perifolliculitis Capitis Abscedens et Suffodiens Treatment with Tumor Necrosis Factor Inhibitors and Baricitinib: A Case Report and Literature Review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1132574"},{"key":"ref_43","first-page":"e57650","article-title":"Eruptive Pruritic Papular Porokeratosis (EPPP) Presenting as a Rare Facial Manifestation Associated With COVID-19: A Case Report","volume":"16","author":"Aryal","year":"2024","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdcr.2021.06.028","article-title":"Baricitinib Rapidly and Sustainably Relieves a Patient from Chronic Pruritus of Unknown Origin Refractory to Dupilumab","volume":"15","author":"Buttgereit","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/ddg.15374","article-title":"Complete response of actinic prurigo to oral baricitinib","volume":"22","year":"2024","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/pde.15643","article-title":"Successful Treatment of Actinic Prurigo with Baricitinib in an 8-year-old Child: A Case Report","volume":"41","author":"Malekan","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.25259\/IJDVL_643_2023","article-title":"Lipodystrophia Centrifugalis Abdominals Infantilis Presenting as a Giant Ulceration and Treatment with Hydroxychloroquine and Baricitinib","volume":"90","author":"Zhao","year":"2024","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e35547","DOI":"10.1016\/j.heliyon.2024.e35547","article-title":"Case Report: A Therapeutic Attempt to Treat Morbihan Disease with Baricitinib","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ced\/llac110","article-title":"Rapid Improvement of Refractory Generalized Granuloma Annulare with the Janus Kinase Inhibitor Baricitinib in Two Patients","volume":"48","author":"Kim","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zheng, J., Ding, Y., Chen, Y., Shi, Y., and Gao, Y. (2024). Effectiveness of Baricitinib in Acquired Reactive Perforating Collagenosis: A Case Report. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1388274"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CCID.S396430","article-title":"Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy","volume":"16","author":"Li","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of Vitiligo with Oral Baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"103300","DOI":"10.1016\/j.annder.2024.103300","article-title":"Vitiligo Treated with Oral Baricitinib and Heliotherapy: A Case Series","volume":"151","author":"Reviron","year":"2024","journal-title":"Ann. Dermatol. V\u00e9n\u00e9r\u00e9ologie"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/all.16512","article-title":"Integrated Efficacy and Safety Analysis of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis","volume":"80","author":"Paller","year":"2025","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis from the Phase II and Phase III Clinical Trial Program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/jdv.19378","article-title":"Real-world Effectiveness of Abrocitinib Treatment in Patients with Difficult-to-treat Atopic Dermatitis","volume":"37","author":"Olydam","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/PPA.S451007","article-title":"Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report","volume":"18","author":"Teng","year":"2024","journal-title":"Patient Prefer. Adherence"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CCID.S446369","article-title":"Abrocitinib as a Novel Treatment for Multiple Skin Disorders: 3 Case Reports and a Scoping Review","volume":"17","author":"Chen","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2434094","DOI":"10.1080\/09546634.2024.2434094","article-title":"Janus Kinase 1 Inhibitor Abrocitinib for Isolated Nail Lichen Planus: A Case Report and Literature Review","volume":"35","author":"He","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/CCID.S520633","article-title":"Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib","volume":"18","author":"Luo","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2050313X251320469","DOI":"10.1177\/2050313X251320469","article-title":"Recalcitrant Vulvar Lichen Planus Cleared on Abrocitinib: A Case Report","volume":"13","author":"DeBiasio","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdcr.2024.02.010","article-title":"Treatment of Plasma Cell Balanitis Associated with Male Genital Lichen Sclerosus Using Abrocitinib","volume":"46","author":"Xiong","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2025.02.022","article-title":"Pyoderma Gangrenosum Treated with Oral Abrocitinib in a 54-Year-Old Woman: A Case Report","volume":"60","author":"Estrella","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2147\/CCID.S517299","article-title":"Abrocitinib Treatment for Localized Type of Generalized Pustular Psoriasis: A Case Report","volume":"18","author":"Yang","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2437259","DOI":"10.1080\/09546634.2024.2437259","article-title":"Successful Treatment of SAPHO Syndrome with Oral Abrocitinib: A Case Report","volume":"35","author":"Lin","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2242706","DOI":"10.1080\/09546634.2023.2242706","article-title":"Successful Treatment of Alopecia Universalis with Abrocitinib: A Case Report","volume":"34","author":"Zhang","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2022.02.027","article-title":"A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib","volume":"22","author":"Zhao","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/JAA.S458684","article-title":"Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up","volume":"17","author":"Liu","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1111\/1346-8138.17232","article-title":"Oral Abrocitinib in the Treatment of Refractory Dissecting Cellulitis of the Scalp: A Case Report","volume":"51","author":"Jin","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1097\/MJT.0000000000001671","article-title":"Effectiveness of Abrocitinib in a Patient with Chronic Actinic Dermatitis","volume":"31","author":"Jin","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.2147\/CCID.S433561","article-title":"A Case of Perioral Dermatitis Successfully Treated with Abrocitinib","volume":"16","author":"Teng","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdcr.2025.02.001","article-title":"Abrocitinib for Treatment of Solid Facial Edema","volume":"59","author":"Baeck","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Xu, B., Xu, Z., Ye, S., Sun, H., Zhao, B., Wu, N., and Wu, J. (2023). JAK1 Inhibitor Abrocitinib for the Treatment of Steroid-Induced Rosacea: Case Series. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1239869"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Zhang, T., Liu, X., Zhang, L., and Jiang, X. (2024). Treatment of Rosacea with Upadacitinib and Abrocitinib: Case Report and Review of Evidence for Janus Kinase Inhibition in Rosacea. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1416004"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.2147\/CCID.S440138","article-title":"Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report","volume":"16","author":"Ren","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2147\/CCID.S522317","article-title":"A Case of Intense Pulsed Light Aggravated Rosacea Successfully Treated by Abrocitinib","volume":"18","author":"Mao","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2147\/CCID.S522469","article-title":"Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report","volume":"18","author":"Fu","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/CCID.S524045","article-title":"Successful Treatment of Delayed Onset Nodules After Dermal Fillers Injection with Abrocitinib: A Case Report","volume":"18","author":"Li","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2556487","DOI":"10.1080\/09546634.2025.2556487","article-title":"Abrocitinib Combined with Low-Dose Corticosteroids in the Management of Tattoo-Related Cutaneous Sarcoidosis: A Case Report","volume":"36","author":"Geng","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2313090","DOI":"10.1080\/09546634.2024.2313090","article-title":"Oral Abrocitinib in the Treatment of Granuloma Annulare: A Case Report","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_82","first-page":"841","article-title":"Successful treatment of recalcitrant generalized granuloma annulare with the JAK inhibitor abrocitinib","volume":"22","author":"Michels","year":"2024","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdcr.2025.06.023","article-title":"Pseudorheumatoid Nodules Treated with Abrocitinib","volume":"63","author":"Bizimungu","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2050313X241231527","DOI":"10.1177\/2050313X241231527","article-title":"Rapid Resolution of Non-Segmental Vitiligo in a Patient Treated with Abrocitinib: A Case Report","volume":"12","author":"Satkunanathan","year":"2024","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/JAA.S492614","article-title":"Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report","volume":"17","author":"Shao","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2528344","DOI":"10.1080\/09546634.2025.2528344","article-title":"Vitiligo Exacerbation during Upadacitinib Treatment for Atopic Dermatitis and Improvement Following a Switch to Abrocitinib: A Case Report","volume":"36","author":"Wang","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/CCID.S470641","article-title":"Abrocitinib Monotherapy for Refractory Prurigo Nodularis: Report of Two Successful Cases","volume":"17","author":"Liang","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e8606","DOI":"10.1002\/ccr3.8606","article-title":"Successful Treatment of Refractory Prurigo Nodularis with Abrocitinib","volume":"12","author":"Sun","year":"2024","journal-title":"Clin. Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Du, N., Wang, D., Yang, J., Zhang, Y., Lyu, X., Min, W., and Zhao, S. (2024). Case Report: Exploration of Abrocitinib in the Treatment of Refractory Chronic Spontaneous Urticaria: A Case Series. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1466058"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2050313X251350332","DOI":"10.1177\/2050313X251350332","article-title":"Treatment of Hailey-Hailey Disease with the Janus Kinase Inhibitor Abrocitinib: A Case Report","volume":"13","author":"Gunyon","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2447883","DOI":"10.1080\/09546634.2024.2447883","article-title":"Abrocitinib Alleviates the Symptoms of Netherton Syndrome and Is Well Tolerated","volume":"36","author":"Tang","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/jdv.20399","article-title":"Clearance of Darier Disease Lesions in a Patient with Concomitant Atopic Dermatitis Treated with Abrocitinib","volume":"39","author":"Bianco","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.2147\/CCID.S485694","article-title":"Combined Abrocitinib and Acitretin Therapy for Darier\u2019s Disease: A Case Report","volume":"17","author":"Ye","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1111\/ijd.16698","article-title":"Treatment of Primary Cutaneous Lichenoid Amyloidosis with Abrocitinib: A Pilot Study in Two Cases","volume":"62","author":"Bai","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Huang, D., and Gao, Y. (2024). Case Report: Abrocitinib: A Potential Therapeutic Option for Lichen Amyloidosis Associated with Atopic Dermatitis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1477664"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/1346-8138.17284","article-title":"Two Cases of Eosinophilic Pustular Folliculitis Successfully Treated with Abrocitinib","volume":"51","author":"Cai","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jdcr.2025.07.005","article-title":"The Treatment for Acquired Reactive Perforating Collagenosis with Abrocitinib: A Case Report","volume":"64","author":"Liu","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/CCID.S455060","article-title":"A Case of Persistent Pityriasis Rosea Successfully Treated by a Short Course of Therapy with Abrocitinib","volume":"17","author":"Wu","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.2147\/CCID.S424310","article-title":"A Report of Eruptive Pruritic Papular Porokeratosis Treated with Abrocitinib","volume":"16","author":"Xia","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Huang, I.-H., Chung, W.-H., Wu, P.-C., and Chen, C.-B. (2022). JAK-STAT Signaling Pathway in the Pathogenesis of Atopic Dermatitis: An Updated Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1068260"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2560502","DOI":"10.1080\/09546634.2025.2560502","article-title":"Off-Label Use of Upadacitinib in Dermatology: A Review","volume":"36","author":"Yu","year":"2025","journal-title":"J. Dermatol. Treat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of Action, Clinical, and Translational Science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Parmentier, J.M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H.S., Padley, R.J., George, J.S., and Hyland, D. (2018). In Vitro and in Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494). BMC Rheumatol., 2.","DOI":"10.1186\/s41927-018-0031-x"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/exd.14226","article-title":"The Inflammation in Cutaneous Lichen Planus Is Dominated by IFN-\u03d2 and IL-21\u2014A Basis for Therapeutic JAK1 Inhibition","volume":"30","author":"Pietschke","year":"2021","journal-title":"Exp. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdcr.2025.02.029","article-title":"Treatment of Recalcitrant Hypertrophic Lichen Planus with Upadacitinib","volume":"59","author":"Schundler","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jdcr.2024.01.007","article-title":"Unilateral Blaschkoid Lichen Planus Successfully Treated with Upadacitinib","volume":"45","author":"Rosenbaum","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jdcr.2025.05.041","article-title":"Oral Lichen Planus Treated with Upadacitinib: A Case Series","volume":"63","author":"Noot","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamadermatol.2024.0755","article-title":"Treatment of Keratosis Lichenoides Chronica with Upadacitinib","volume":"160","author":"Tang","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.2147\/CCID.S534496","article-title":"Successful Treatment of Nail Lichen Planus by the Janus Kinase 1 Upadacitinib and Literature Review","volume":"18","author":"Zhao","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jdcr.2025.01.014","article-title":"Successful Treatment of Recalcitrant Cutaneous Lichen Planus and Unusual Variants with Upadacitinib: A Case Series and a Literature Review of Systemic Janus Kinase Inhibitors Use in Cutaneous Lichen Planus and Lichen Planopilaris","volume":"59","author":"McNamara","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jdcr.2025.06.051","article-title":"Bullous Pityriasis Lichenoides et Varioliformis Acuta Successfully Treated with Upadacitinib","volume":"64","author":"Houpe","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Salvi, I., Parodi, A., Cozzani, E., and Burlando, M. (2024). Case Report: Psoriasiform Eczema with Immune-Mediated Comorbidities Treated with Upadacitinib. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1432233"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2050313X251317763","DOI":"10.1177\/2050313X251317763","article-title":"Palmoplantar Plaque Psoriasis Responsive to Upadacitinib: A Report of Two Cases","volume":"13","author":"Choi","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2050313X251317811","DOI":"10.1177\/2050313X251317811","article-title":"Dupilumab-Induced Psoriasis in a Patient with Atopic Dermatitis Successfully Treated with Upadacitinib: A Case Report","volume":"13","author":"Cirone","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2246604","DOI":"10.1080\/09546634.2023.2246604","article-title":"Upadacitinib in Nail Psoriasis: A Case Report","volume":"34","author":"Wang","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdcr.2023.11.023","article-title":"Upadacitinib as a Treatment for Co-Existent Allergic Contact Dermatitis and Psoriasis","volume":"44","author":"Song","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jdcr.2024.05.009","article-title":"Upadacitinib for the Treatment of Psoriasiform and Spongiotic Dermatitis: A Multicenter Case Series","volume":"49","author":"Shahriari","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1529-8019.2012.01488.x","article-title":"Management of neutrophilic dermatoses","volume":"25","author":"Schadt","year":"2012","journal-title":"Dermatol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdcr.2023.05.016","article-title":"Resolution of Therapy-Resistant Pyoderma Gangrenosum with Upadacitinib","volume":"37","author":"Dens","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ge, G., Zhan, L., Huang, M., Su, F., Chen, J., and Dong, J. (2025). Case Report: Treatment of Facial Pyoderma Gangrenosum with Upadacitinib. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1665013"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jdcr.2025.08.003","article-title":"Sweet Syndrome Successfully Treated with Upadacitinib","volume":"65","author":"Doan","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdcr.2024.11.021","article-title":"A Case of Papuloerythroderma of Ofuji Treated with Upadacitinib","volume":"55","author":"Lei","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2331785","DOI":"10.1080\/09546634.2024.2331785","article-title":"A Case of Generalized Eosinophilic Pustular Folliculitis: Treatment with JAK Inhibitor","volume":"35","author":"Zheng","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis Suppurativa: New Insights into Disease Mechanisms and an Evolving Treatment Landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_125","first-page":"e52377","article-title":"Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib","volume":"16","author":"Islam","year":"2024","journal-title":"Cureus"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jdcr.2024.08.002","article-title":"The Utility of Upadacitinib to Treat Refractory Hidradenitis Suppurativa in an Obese Patient","volume":"65","author":"Islam","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2024.12.008","article-title":"Dual Immunomodulator Therapy with Adalimumab and Upadacitinib to Treat Recalcitrant Hidradenitis Suppurativa","volume":"56","author":"Islam","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_128","first-page":"e85255","article-title":"A Case of Refractory Hidradenitis Suppurativa Successfully Treated with Upadacitinib","volume":"17","author":"Takei","year":"2025","journal-title":"Cureus"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jdcr.2023.03.004","article-title":"Refractory Pityriasis Rubra Pilaris Treated with Upadacitinib","volume":"35","author":"Song","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2050313X231160927","DOI":"10.1177\/2050313X231160927","article-title":"Pityriasis Rubra Pilaris Partially Responsive to Treatment with Upadacitinib: A Case Report","volume":"11","author":"Saad","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1111\/jdv.19762","article-title":"Successful Treatment of Erythrodermic Pityriasis Rubra Pilaris with Upadacitinib","volume":"38","author":"Li","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous Lupus Erythematosus: New Insights into Pathogenesis and Therapeutic Strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2147\/CCID.S419344","article-title":"Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report","volume":"16","author":"Hu","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK Inhibitor Improves Type I Interferon Induced Damage: Proof of Concept in Dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2391445","DOI":"10.1080\/09546634.2024.2391445","article-title":"A Case of Refractory Anti-MDA5-Positive Amyopathic Dermatomyositis Successfully Treated with Upadacitinib","volume":"35","author":"Huang","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ijd.17135","article-title":"A Case of Refractory Amyopathic Dermatomyositis Successfully Treated with Upadacitinib","volume":"63","author":"Maione","year":"2024","journal-title":"Int. J. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdcr.2024.06.033","article-title":"Successful Treatment of Refractory Amyopathic Dermatomyositis with Upadacitinib in Prior JAK Inhibitor Failure","volume":"51","author":"Sohn","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2050313X251343300","DOI":"10.1177\/2050313X251343300","article-title":"Upadacitinib as a Potential Management Option for Diffuse Cutaneous Systemic Sclerosis: A Case Report","volume":"13","author":"Sarfaraz","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ced\/llad348","article-title":"JAK-Ing up Chronic Actinic Dermatitis with Upadacitinib","volume":"49","author":"Pappa","year":"2024","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/skinhd\/vzaf049","article-title":"Three Cases of Chronic Photodermatitis Successfully Treated with Upadacitinib","volume":"5","author":"AlHammadi","year":"2025","journal-title":"Skin Health Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2050313X251341558","DOI":"10.1177\/2050313X251341558","article-title":"Refractory Pediatric Actinic Prurigo Successfully Treated with Upadacitinib: A Case Report","volume":"13","author":"Morissette","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Almaghrabi, M.M., Kalantan, N., Alshareef, A., and Jfri, A. (2025). Case Report: Upadacitinib in the Management of Refractory Urticarial Vasculitis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1669513"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2147\/CCID.S556844","article-title":"Successful Treatment of Refractory Livedoid Vasculopathy with Upadacitinib: A Case Report","volume":"18","author":"Wang","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2302394","DOI":"10.1080\/09546634.2024.2302394","article-title":"Upadacitinib for the Management of Bullous Pemphigoid Coexisting with Psoriasis Vulgaris: A Case Report and Literature Review","volume":"35","author":"Su","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jdcr.2023.01.037","article-title":"Upadacitinib for Prurigo Nodularis","volume":"48","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_147","first-page":"e106","article-title":"Treatment of Chronic Prurigo with Upadacitinib: A Case Series","volume":"38","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40257-021-00636-1","article-title":"Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options","volume":"23","author":"Joshi","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdcr.2023.01.027","article-title":"A Case of Generalized Granuloma Annulare Treated with Upadacitinib","volume":"34","author":"Slater","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_150","first-page":"8859178","article-title":"Successful Treatment of Refractory Generalized Granuloma Annulare with Upadacitinib","volume":"2024","author":"Coican","year":"2024","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e70092","DOI":"10.1111\/srt.70092","article-title":"Effective Treatment of Recalcitrant Generalized Papular Granuloma Annulare with Upadacitinib Monotherapy: A Case Report and Literature Review","volume":"30","author":"Chen","year":"2024","journal-title":"Skin Res. Technol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2010.11.061","article-title":"Vitiligo: A Comprehensive Overview","volume":"65","author":"Alikhan","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/CCID.S458592","article-title":"Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series","volume":"17","author":"He","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/CCID.S467026","article-title":"Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report","volume":"17","author":"Mu","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdcr.2024.01.033","article-title":"Upadacitinib and Its Role in the Treatment of Vitiligo: A New Possible Therapeutic Perspective","volume":"46","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdcr.2022.08.014","article-title":"Effective Treatment of Alopecia Universalis with Oral Upadacitinib","volume":"31","author":"Youssef","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jdcr.2023.09.011","article-title":"Refractory Hailey\u2013Hailey Disease Cleared with Upadacitinib","volume":"41","author":"Murphy","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2024.06.019","article-title":"Recalcitrant Cutaneous Sarcoidosis Treated with Upadacitinib: Case Report","volume":"51","author":"Safadi","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jdcr.2022.10.010","article-title":"A Case of Erythrodermic Mycosis Fungoides Responding to Upadacitinib","volume":"30","author":"Castillo","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e02300","DOI":"10.1016\/j.idcr.2025.e02300","article-title":"Atypical Tinea Corporis with Id Reaction: A Case Report and Successful Treatment with Upadacitinib","volume":"41","author":"Mao","year":"2025","journal-title":"IDCases"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2050313X251350370","DOI":"10.1177\/2050313X251350370","article-title":"Upadacitinib in Refractory Cutaneous Pseudolymphoma: A Case Report","volume":"13","author":"Danese","year":"2025","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2147\/CCID.S540221","article-title":"Upadacitinib Coadministered with Methylprednisolone for Effective Treatment of SJS\/TEN Overlap Syndrome: A Case Report","volume":"18","author":"Zhou","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdcr.2023.02.010","article-title":"Treatment of Persistent Erythema Multiforme with Upadacitinib: A Novel Therapeutic Approach","volume":"34","author":"Deutsch","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdcr.2023.02.024","article-title":"Upadacitinib as a Treatment for Chronic Pruritus Secondary to Polycythemia Vera after Failure with Dupilumab","volume":"35","author":"Wachuku","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40268-024-00487-1","article-title":"A Case Report of JAK Inhibitors Therapy for Adult-Onset Still\u2019s Disease with Persistent Pruritic Lesions","volume":"24","author":"Tang","year":"2024","journal-title":"Drugs RD"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b\u20133 Trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/jdv.20526","article-title":"Long-term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO\u2014LT Phase 3, Open-label Study","volume":"39","author":"Tziotzios","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/bjd\/ljae365","article-title":"Efficacy and Safety of the Oral Janus Kinase 3\/Tyrosine Kinase Expressed in Hepatocellular Carcinoma Family Kinase Inhibitor Ritlecitinib over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb\/III and Long-Term Phase III Clinical Studies in Alopecia Areata","volume":"192","author":"Piliang","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/1346-8138.17886","article-title":"Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study","volume":"52","author":"Huang","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jdcr.2025.05.017","article-title":"Erosive Oral Lichen Planus Successfully Treated with JAK3\/TEC Inhibitor Ritlecitinib: A Case Report","volume":"63","author":"Katz","year":"2025","journal-title":"JAAD Case Rep."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Tong, Z., Wu, Z., Zeng, X., Huang, F., Gong, T., and Ji, C. (2024). Ritlecitinib Rescues Exacerbated Vitiligo during the JAK1 Inhibitor Therapy: More than a Coincidence?. Indian J. Dermatol. Venereol. Leprol., ahead of print.","DOI":"10.25259\/IJDVL_348_2024"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Bianco, M., D\u2019Oria, F., Falcidia, C., Foggi, G., Matteodo, E., Di Giulio, S., Facheris, P., Ibba, L., Perugini, C., and Valenti, M. (2025). New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review. Medicina, 61.","DOI":"10.3390\/medicina61040631"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:14:01Z","timestamp":1769058841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/1\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":172,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["medicina62010190"],"URL":"https:\/\/doi.org\/10.3390\/medicina62010190","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}